Candel Therapeutics(CADL.US)

Last Updated 19:00:00 ET
longbridge loading

Candel Therapeutics Eyes Year-End BLA After Strong Prostate Cancer Data

Market Beat·
US
CADL
+2.15%
US
LABU
+10.78%
US
IBB
+1.91%
Market Beat·
US
CADL
+2.15%
US
LABU
+10.78%
US
IBB
+1.91%

Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data

benzinga_article·
US
CADL
+2.15%
US
LABU
+10.78%
US
SBIO
+3.67%
benzinga_article·
US
CADL
+2.15%
US
LABU
+10.78%
US
SBIO
+3.67%

Candel Therapeutics Highlights Phase 3 Prostate Cancer Data

Tip Ranks·
US
CADL
+2.15%
US
SBIO
+3.67%
US
XBI
+3.63%
Tip Ranks·
US
CADL
+2.15%
US
SBIO
+3.67%
US
XBI
+3.63%

Candel Therapeutics | 10-Q: FY2026 Q1 Revenue: USD 0

Earnings Watch·
US
CADL
+2.15%
Earnings Watch·
US
CADL
+2.15%

Candel Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0

Earnings Watch·
US
CADL
+2.15%
Earnings Watch·
US
CADL
+2.15%
© 2026 Longbridge｜Disclaimer